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Abstract   
Contrasting results have been reported about the prevalence of thyroid autoimmunity (AT) and 
dysfunction (TD) in patients with psoriatic arthritis (PsA). 
In this study we pointed to evaluate the incidence of new cases of clinical and subclinical TD in a broad 
group of patients with PsA, versus a control group, matched by age and gender belonging to the same 
geographic area.  
PsA patients with TD were excluded firstly, and new cases of thyroid disorders were evaluated in 97 
PsA patients and 97 matched controls, who had comparable iodine intake (median follow-up of 74 
months in PsA versus 92 in controls).  
A raised rate of new cases of hypothyroidism, TD, positive anti-thyroid peroxidase (AbTPO) 
antibodies, and appearance of a small hypoechoic thyroid pattern in PsA, especially in female gender, 
compared to controls has been evidenced. Risk factors in female gender for the development of TD are: 
thyroid-stimulating hormone (TSH) within the normal range but at the higher limit, positive AbTPO, 
and small thyroid volume. 
To sum up, thyroid function follow-up and suitable treatments should be performed regularly in female 
patients at high risk (TSH within the normal range but at the higher limit, positive AbTPO, hypoechoic 
and small thyroid). 
 
Keywords: psoriatic arthritis, thyroid autoimmunity, AbTPO, thyroid hypoechogenicity, 
hypothyroidism. 
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Introduction 
Psoriatic arthritis (PsA) has been shown associated with thyroid autoimmune disorders and 
hypothyroidism. 
A higher prevalence of thyroid anti-microsomal antibodies positivity has been shown in 42 PsA 
patients in a study by Bianchi and coworkers [1]. Moreover, we have demonstrated [2] a higher 
prevalence of thyroid autoimmunity [positive anti-thyroid peroxidase (AbTPO) antibodies, thyroid 
hypoechogenicity] in PsA patients than in controls. However other studies reported contrasting results 
[3-5]. For example a study reported thyroid autoimmunity in patients with psoriasis was no different 
from that found in healthy individuals [4]. The main aim of this study was to evaluate the incidence of 
new cases of clinical and subclinical thyroid dysfunction (TD) in a wide group of patients with PsA 
versus an age- and sex-matched control group from the same geographic area. 
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Methods 
A thyroid evaluation was conducted in 132 patients with PsA consecutively referred to the 
Rheumatology Unit and the Internal Medicine of the University of Pisa (1995-2012). The diagnosis of 
PsA was done according to Vasey and Espinoza criteria [6].  
Disease activity was evaluated by: ACR joint count, serum C-reactive protein, Health Assessment 
Questionnaire, morning stiffness duration, presence of spinal and nocturnal pain [7].
 
The criteria of exclusion from the study were: 1) PsA patients who had had previous treatment with 
radiotherapy in the regions of neck or mediastinum regions, or with biologics; 2) PsA patients having 
clinical or subclinical hypothyroidism, clinical or subclinical hyperthyroidism (or Graves’ disease). 
Ninety-seven patients with PsA without TD had the eligibility criteria for the longitudinal study. 
Patients were additionally assessed one or more times, at least 1 year after the first evaluation, and 
subsequently every year.  
The follow-up interval (median) from the initial evaluation was 74 months (range 13-171 months). 
The 97 eligible PsA patients were matched by age and gender, one-to-one, with controls (without TD), 
from the same geographic context (North-West Tuscany), having a comparable iodine intake (that is a 
risk factor for thyroid autoimmune diseases outcome).  
Urinary iodine excretion [8] was evaluated in 32 patients with PsA and in 35 control subjects, and it 
was not significantly different (median, 91.0 µg/L; interquartile range (IR), 43.3 – 161.2 µg/L and 
median, 94.0 µg/L; IR, 37.2–157.4 µg/L, respectively; not significant [NS]).  
Controls were selected (by random selection and assignment) from more than 2000 subjects extracted 
from a survey of thyroid disorders (population-based), firstly evaluated in 1994 and then again (with a 
complete thyroid re-evaluation) in 2002-2003. The follow-up interval (median) from the initial 
evaluation was 92 months (range 84-119 months). 
PsA and control subjects were reassessed by: 1. physical examination; 2. thyroid ultrasonography [9]; 
3. serum free thyroxine (FT4), free triiodothyronine (FT3) (AMERLEX-MAB FT4/FT3 Kit; 
Amersham, UK), thyroid-stimulating hormone (TSH) (normal limits 0.3-3.6 µU/mL) (DiaSorin, USA), 
AbTPO and AbTg antibodies (ICN Pharmaceuticals, USA; positivity > 100 IU/mL) (each dosage was 
done in triplicate).  
In the case of an appearance of TD in the follow-up of PsA patients, they were treated properly and 
excluded from the study.  
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Institutional ethic committee approved the study, and subjects taking part to it gave their informed 
consent.  
Normally distributed variables were compared by ANOVA, or mean group values by Mann-Whitney U 
test, while categorical variables were evaluated by χ2 test. Age, gender, smoking, thyroid 
hypoechogenicity, TSH, positive AbTg or AbTPO, thyroid volume (at the initial evaluation) were 
included as variables (independent) in a logistic regression analysis in PsA subjects, and 
hypothyroidism (dependent variable) at last evaluation.  
 
Results 
The basal thyroid status of PsA patients participating to the study and matched controls is described in 
Table 1.  
Slightly higher, but significant, TSH, AbTg and AbTPO were reported in PsA patients. The prevalence 
of indices of thyroid autoimmunity, such as subjects with positive AbTPO, AbTg, thyroid volume < 6 
mL, or a thyroid hypoechoic pattern, were more elevated, even if not significantly, in the PsA group 
with respect to control subjects.  
At the last evaluation (upon a median of 74 and 92 months, respectively, in patients with PsA and 
controls: P < 0.01, ANOVA) TSH, AbTPO and AbTg levels were significantly more elevated in the 
PsA patients than in controls (Table 2). Subclinical hypothyroidism was more frequent (P < 0.05) in 
PsA patients with respect to control subjects, while subclinical hyperthyroidism was more prevalent in 
PsA without reaching the statistical significance. Overall prevalence of TDs (clinical or subclinical 
hypo- and hyper-thyroidism) was more common (P < 0.05) in PsA, such as the one of subjects showing 
a thyroid hypoechoic pattern, AbTPO-positivity and volume < 6 mL.  
In Table 3 we have shown the prevalence and the incidence of new cases of thyroid disorders. TD, 
subclinical hypothyroidism, hypothyroidism, a thyroid hypoechoic pattern, AbTPO-positivity, thyroid 
autoimmunity or a small thyroid (< 6 mL) were more frequent  (P < 0.05) in the PsA group.  
All PsA patients with subclinical hypothyroidism showed polyarticular involvement  (P < 0.05) and a 
longer duration of the disease than other PsA patients (years 18±17 versus 9±9, P = 0.005). PsA disease 
activity was not related with the presence of any kind of thyroid disorders.  
At the conclusion of the follow-up, in PsA patients there was a significant association among 
hypothyroidism, positive AbTPO (P < 0.014), a small thyroid (< 6 mL) (P < 0.009), and 
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hypoechogenicity (P < 0.021) (all by χ2), but not with any other thyroid parameter. Furthermore, 
clinical parameters of PsA patients and AbTg, AbTPO, or other studied parameters, were not 
associated.  
The number of euthyroid patients with PsA and control subjects who were “thyroid autoimmunity–
negative” (“clean”) at entry were, respectively, 78 and 86. The number of new cases of subclinical 
hypothyroidism or hyperthyroidism in these clean patients with PsA were 4 and 0, respectively (4 of 78 
[5.1%]), whereas in clean control subjects they were 0 and 0, respectively (0 of 86 [0%]); the 
difference was statistically significant (Pearson P = 0.033, Mantel-Hanszel P = 0.034; Fisher’s exact 
test, P = 0.049) (Table 4). No other dysfunctions were observed in the clean patients. 
In PsA, the logistic regression analysis [considering: gender, age, TSH, AbTg-positivity, AbTPO-
positivity, thyroid volume, thyroid hypoechogenicity (presence/absence),  (all at the first examination) 
as independent variables, and hypothyroidism (at last visit) as the dependent variable] evidenced that 
the onset of hypothyroidism was linked to gender (female) [coefficient, 0.901; Exp(coef), 2.423; 95% 
lower, 1.304; 95% upper, 4.89; P = 0.01], initial normal TSH but at the higher limit [coefficient, 0.876; 
Exp(coef), 2.264; 95% lower, 1.126; 95% upper, 4.07; P = 0.036] and AbTPO positivity [coefficient, 
0.871; Exp(coef), 2.012; 95% lower, 1.095; 95% upper, 4.176; P = 0.027] (Table 5). 
No association was found among thyroid dysfunctions or autoimmunity, and PsA disease activity. 
In controls, the logistic regression analysis [considering: gender, age, TSH, AbTg-positivity, AbTPO-
positivity, thyroid volume, thyroid hypoechogenicity (presence/absence), (all at the first examination) 
as independent variables, and hypothyroidism (at last visit) as the dependent variable] did not show any 
significant statistical association.  
 
Discussion 
In this study we demonstrate a higher incidence of new cases of AbTPO-positivity, hypothyroidism, 
TD, hypoechoic thyroid pattern, and thyroid autoimmunity in PsA patients versus control subjects; 
despite a significantly longer follow-up in the control group. A polyarticular involvement and longer 
disease duration have been shown in the PsA patients with subclinical hypothyroidism, too. 
Interestingly, it was seen a similar incidence of new cases of AbTPO, and hypothyroidism in controls 
as the one evidenced in other epidemiological studies [10-12], for this reason control group is not 
biased versus a low prevalence of AT [13].  
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As reported by other papers, and by our preceding transversal study [2, 14], mean TSH level, a small 
thyroid volume, a thyroid hypoechoic pattern, and antithyroid antibodies were significantly more 
elevated in PsA patients than in controls.  
The logistic regression analysis demonstrated in PsA that the onset of hypothyroidism was associated 
with the female gender, TSH within the normal range but at the higher limit, AbTPO-positivity, and 
small thyroid volume, as shown in the general population [10-12].  
At least in part, the significant differences in the baseline autoimmune thyroid parameters between PsA 
patients and controls could be the reason of the more elevated incidence of hypothyroidism in PsA 
patients. 
It is well known that autoimmune disorders are associated [15], although its pathogenetic basis is not 
known [16, 17]. 
In PsA a Th1 immune predominance has been shown in the first phases of the disease [21]. CXCL10 
(the prototype Th1 chemokine) is determinant in the pathogenesis of psoriasis and PsA. CXCR3 and 
CXCL10 were demonstrated in keratinocytes and the infiltrate from active dermal psoriatic plaques; an 
effective therapy of active plaques reduced CXCL10 expression in plaques. High circulating CXCL10 
levels have been observed in psoriasis, with a Th1 immune predominance in the first phases of the 
disease; while CXCL10 levels decline in long lasting psoriasis [21]. Moreover, circulating CXCL10 
levels in psoriatic patients are higher (P < 0.05) in the presence of AT [22, 23]. On the basis of the 
above mentioned observations, it has been speculated that CXCL10 may be a good circulating marker 
to control psoriasis activity and/or progression, and selective and potent CXCR3 or CXCL10 
antagonists have been assessed in autoimmune diseases, suggesting their potential use also in this 
disease [21]. 
The common above reported Th1 immune predominance profile in the initial phases of both PsA, and 
AT, under the influence of environmental and genetic conditions, may be the pathogenetic basis of the 
onset of autoimmune phenomena that involve various organs in the same person [24]. 
To sum up, an elevated incidence of new cases of TD, hypothyroidism, positive AbTPO, appearance of 
a hypoechoic and small thyroid have been reported in PsA patients, particularly in females, versus 
controls. These data suggest that PsA patients are at risk for the development of new thyroid 
autoimmune disorders, and consequently thyroid dysfunctions. In fact, risk factors in females for the 
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development of TD are: TSH within the normal range but at the higher limit, a small thyroid volume, 
or positive AbTPO.  
We suggest that approximately every year, thyroid function (and suitable treatments) should be 
assessed in female patients with a major risk (TSH within the normal range but at the higher limit, 
positive AbTPO, a small or hypoechoic thyroid). 
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Table 1. Comparison of the basal thyroid status between patients with psoriatic arthritis (PsA), 
and controls from the general population (C).  
 PsA C P 
N. 97 97  
Age (years) 56 ± 12 57 ±11 ns 
Gender (F/M) 46/51 46/51 ns 
TSH (µU/mL) 2.1 ± 0.7 1.1 ± 0.8 0.042a 
FT4 (ng/dL) 0.9 ± 0.4 1.1 ± 0.4 ns 
FT3 (pg/mL) 2.5 ± 0.7 2.8 ± 1.1 ns 
AbTg (IU/mL) median 141 
(IR, 12-472) 
median 11 
(IR, 5-79) 
0.014a 
AbTPO (IU/mL) median 121 
(IR, 21-572) 
median 21 
(IR, 8-91) 
0.026a 
Subclinical hypothyroidism 0% 0% ns 
Clinical hypothyroidism 0% 0% ns 
Subclinical hyperthyroidism 0% 0% ns 
Clinical hyperthyroidism 0% 0% ns 
Thyroid dysfunction 0% 0% ns 
AbTg+ (9) 9% (5) 5% ns 
AbTPO+ (14) 14% (8) 8% ns 
Hypoechoic pattern (16) 16% (9) 9% ns 
Thyroid autoimmunity (19) 19% (11) 11% ns 
Thyroid volume (mL) 11 ± 8 12 ± 7 ns 
Thyroid volume > 20 mL (7) 7% (9) 9% ns 
Thyroid volume < 6 mL (9) 9% (4) 4% ns 
Thyroid nodules (51) 53 % (56) 58% ns 
AbTg+: antithyroglobulin antibodies > 100 IU/ml; AbTPO+: 
antithyroperoxidase antibodies > 100 IU/ml; thyroid autoimmunity: AbTg+ 
or AbTPO+ or ultrasonographic diagnosis of thyroiditis; interquartile range 
(IR). P ≤ 0.05= a by ANOVA. 
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Table 2. Comparison of the thyroid status at the last evaluation between patients with psoriatic 
arthritis (PsA), and controls from the general population (C).  
 PsA C P 
N. 97 97  
Age (years) 63 ± 12 65 ±11 ns 
Gender (F/M) 46/51 46/51 ns 
TSH (µU/mL) 2.9 ± 4.1 1.3 ± 1.0 0.018a 
FT4 (ng/dL) 0.8 ± 0.5 1.2 ± 0.6 ns 
FT3 (pg/mL) 2.3 ± 0.8 2.6 ± 1.2 ns 
AbTg (IU/mL) 168 ± 254 25 ± 51 0.016a 
AbTPO (IU/mL) 152 ± 379 41 ± 81 0.023a 
Subclinical hypothyroidism (8) 8% (1) 1% 0.016 
Clinical hypothyroidism (2) 2% (1) 1% ns 
Subclinical hyperthyroidism (7) 7% 2 (2%) ns 
Clinical hyperthyroidism 0% 0% ns 
Thyroid dysfunction (17) 17% (4) 4% 0.002b 
AbTg+ (13) 13% (7) 7% 0.156b 
AbTPO+ (24) 25% (10) 10% 0.008b 
Hypoechoic pattern (27) 28% (11) 11% 0.003b 
Thyroid autoimmunity (33) 34% (15) 15% 0.002b 
Thyroid volume (mL) 10 ± 7 11 ± 10 ns 
Thyroid volume > 20 mL (7) 7% (9) 9% ns 
Thyroid volume < 6 mL (19) 19% 5 (5%) 0.002b 
Thyroid nodules (57) 59% (61) 63% ns 
AbTg+: antithyroglobulin antibodies >100 IU/mL; AbTPO+: 
antithyroperoxidase antibodies >100 IU/mL; thyroid autoimmunity: AbTg+ 
or AbTPO+ or ultrasonographic diagnosis of thyroiditis. P ≤0.05= a by 
ANOVA; by χ2 test (b).   
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Table 3. New cases and incidencea of thyroid disorders in PsA patients at the last evaluation.  
 
 
PsA patients  
number new cases 
(incidence) 
Controls 
number new cases 
(incidence) 
Pb 
 
Subclinical hypothyroidism 8 (13c) 1 (1c) 0.016 
Clinical hypothyroidism 2 (3c) 1 (1c) ns 
Hypothyroidism 10 (17c) 2 (3c) 0.017 
Subclinical  hyperthyroidism 7 (12c) 2 (3c) ns 
Clinical hyperthyroidism 0 (0c) 0 (0c) ns 
Hyperthyroidism 7 (12c) 2 (3c) ns 
Thyroid dysfunction 17 (28 c) 4 (5c) 0.002 
AbTg+ 4 (7c) 2 (3c) ns 
AbTPO+ 10 (17c) 2 (3c) 0.017 
Hypoechoic pattern 11 (18c) 2 (3c) 0.009 
Thyroid autoimmunity 15 (25 c) 4 (5c) 0.007 
Thyroid volume > 20 mL 0 (0c) 0 (0c) ns 
Thyroid volume < 6 mL 10 (17c) 1 (1c) 0.005 
Thyroid nodules 6 (10 c) 5 (7c) ns 
a Incidence is reported in parenthesis. Incidence = [incidence = number of new cases / patients (97) x years of 
follow-up (74 months = 6.2 years) = number of new events / 601 patients per year)] and matched controls 
[incidence = number of new cases / subjects (97) x years of follow-up (92 months = 7.7 years) = number of 
new events / 747 patients per year)].  
b = χ2 (number of new cases).  
c = with respect to 1000 patients with PsA per year. 
AbTPO = anti-thyroperoxidase antibody; AbTPO+ = anti-thyroperoxidase antibodies >100 IU/mL; AbTg = 
anti-thyroglobulin antibody; AbTg+ = anti-thyroglobulin antibodies >100 IU/mL. 
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Table 4. New cases of thyroid disorders in “clean” PsA patients at the last evaluation.  
 
 
“clean” PsA patients 
78  
number new cases  
“clean” Controls 
86 
number new cases  
P 
 
Subclinical hypothyroidism 4 (5.1%) 0  0.049 
Clinical hypothyroidism 0 0 ns 
Subclinical  hyperthyroidism 0 0 ns 
Clinical hyperthyroidism 0  0  ns 
 
P by Fisher’s exact test. 
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Table 5. Results of the logistic regression analysis in PsA patients [considering: gender, age, TSH, AbTg-positivity, 
AbTPO-positivity, thyroid volume, thyroid hypoechogenicity (presence/absence), (all at the first examination) as 
independent variables, and hypothyroidism (at last visit) as the dependent variable].  
 Coefficient Exp (coef) 95% lower 95% upper 
Female gender 0.901 2.423 1.304 4.89 
TSH at the higher limit 0.876 2.264 1.126 4.07 
AbTPO positivity 0.871 2.012 1.095 4.176 
 
 
